Edition:
United States

Amgen Inc (AMGN.O)

AMGN.O on Nasdaq

197.53USD
13 Dec 2018
Change (% chg)

$1.12 (+0.57%)
Prev Close
$196.41
Open
$196.77
Day's High
$197.66
Day's Low
$195.22
Volume
2,129,816
Avg. Vol
2,723,675
52-wk High
$210.19
52-wk Low
$163.31

Chart for

About

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN... (more)

Overall

Beta: 1.40
Market Cap(Mil.): $135,588.20
Shares Outstanding(Mil.): 729.67
Dividend: 1.15
Yield (%): 2.48

Financials

  AMGN.O Industry Sector
P/E (TTM): 16.90 31.13 34.39
EPS (TTM): 11.00 -- --
ROI: 11.98 15.55 14.96
ROE: 26.43 16.92 16.52

Amgen antibody shows promise in myeloma trial, gets FDA fast track

SAN DIEGO Amgen Inc, updating the first trial of its bispecific antibody for multiple myeloma, said on Monday seven out of 10 patients given the second-highest dose of AMG420 responded to the drug, including four with no detectable cancer.

Dec 04 2018

UPDATE 1-Amgen antibody shows promise in myeloma trial, gets FDA fast track

SAN DIEGO Dec 3 Amgen Inc, updating the first trial of its bispecific antibody for multiple myeloma, said on Monday seven out of 10 patients given the second-highest dose of AMG420 responded to the drug, including four with no detectable cancer.

Dec 04 2018

Amgen's AMG420 shows responses in myeloma trial, gets FDA fast track

SAN DIEGO Dec 3 Amgen Inc, updating the first trial of its bispecific antibody for multiple myeloma, on Monday said seven out of ten patients given the second-highest dose of AMG420 responded to the drug, including four with no detectable cancer.

Dec 03 2018

Coherus prices biosimilar to Amgen's Neulasta at 33 percent discount

Coherus BioSciences Inc said on Thursday it would price its biosimilar to Amgen Inc's infection-fighting treatment, Neulasta, at a 33 percent discount.

Nov 08 2018

Coherus prices biosimilar to Amgen's Neulasta at 33 pct discount

Nov 8 Coherus BioSciences Inc said on Thursday it would price its biosimilar to Amgen Inc's infection-fighting treatment, Neulasta, at a 33 percent discount.

Nov 08 2018

Amgen posts higher quarterly EPS, Repatha sales fall short

Amgen Inc on Tuesday said stock buybacks lifted its third-quarter earnings per share, but operating income fell as expenses rose and sales of some key products declined.

Oct 30 2018

UPDATE 2-Amgen posts higher quarterly EPS, Repatha sales fall short

Oct 30 Amgen Inc on Tuesday said stock buybacks lifted its third-quarter earnings per share, but operating income fell as expenses rose and sales of some key products declined.

Oct 30 2018

Amgen quarterly net profit falls as expenses increase; EPS rises

Oct 30 Amgen Inc on Tuesday said its third quarter profit fell as higher expenses offset a lower tax rate and price concessions kept sales of its cholesterol drug Repatha below Wall Street estimates.

Oct 30 2018

UPDATE 1-Amgen cuts U.S. price of cholesterol drug Repatha by 60 percent

Oct 24 Amgen Inc, looking to boost use of its potent cholesterol drug Repatha, has cut the medication's U.S. list price by 60 percent to $5,850, the biotechnology company said on Wednesday.

Oct 24 2018

Amgen cuts price of cholesterol drug Repatha by 60 percent

Amgen Inc, looking to boost use of its potent cholesterol drug Repatha, has cut the medication's U.S. list price by 60 percent to $5,850, the U.S. biotechnology company said on Wednesday.

Oct 24 2018

Earnings vs. Estimates